Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by longrun86on Sep 08, 2023 1:11am
169 Views
Post# 35625525

RE:RE:Adjusted enterprise value = Exelon

RE:RE:Adjusted enterprise value = ExelonThere is no point in Knight going private. The company will have opportunities to grow and may wish to access capital markets (debt or equity).

Knight clearly needs to improve the return profile of its Latam business and if it can demonstrate that there is a path to doing this then the valuation will finally get out of the ditch and back on the road.

I read an interesting article today and the quote said "there are four types of economies: developed, developing, Japan, and Argentina". Let's hope Argentina finally stops screwing around and pegs its currency to the US dollar.

I am hanging around here for the long run but this has not developed from an operating margin perspective as much as I had hoped. I suppose the secret to life is lower expectations so I have lowered mine accordingly for the time being.

LR
<< Previous
Bullboard Posts
Next >>